Are There Changes Ahead for the Generalized Anxiety Disorder Market?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Overview of Generalized Anxiety Disorder
  • Disease Defi nition
  • Diagnosis
  • Pathophysiology of Generalized Anxiety Disorder
    • Serotonin
    • Norepinephrine
    • Gamma-Aminobutyric Acid
    • Glutamate
    • Corticotropin-Releasing Factor
    • Substance P
• Prevalence of Generalized Anxiety Disorder
• Current Therapies for Generalized Anxiety Disorder
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin and Norepinephrine Reuptake Inhibitors
  • Benzodiazepines
• Emerging Therapies for Generalized Anxiety Disorder
  • Sanofi -Aventis' s Saredutant
  • Takeda/Lundbeck' s Lu AA21004
  • Pfi zer' s Lyrica and PD-332334
  • Synosia Therapeutics' Rufi namide
  • Sepracor' s SEP-225441
• Generalized Anxiety Disorder Market: 2007 Statistics and Future Outlook

• 1. Common Symptoms of Generalized Anxiety Disorder
• 2. Common Risk Factors for Generalized Anxiety Disorder
• 3. Therapies Commonly Used to Treat Generalized Anxiety Disorder
• 4. Agents in Development to Treat Generalized Anxiety Disorder
• 5. Sales of Agents to Treat Generalized Anxiety Disorder, 2007

• 1. Structures of the Brain Implicated in Anxiety Disorders
• 2. Prevalent Cases of Generalized Anxiety Disorder in the Major Pharmaceutical Markets, 2007 and 2012